Symptoms and manifestations which led to PGA≥0.5* despite cSLEDAI-2K=0 in a multicentre cohort of 646 patients with lupus
| Patients with PGA≥0.5 and cSLEDAI-2K=0 | 195/646 (30.2%) |
| 1. Patients with subjective findings without objectifiable clinical manifestations likely due to SLE (condition 1) | 157/195 (80.5%) |
| Musculoskeletal domain | 98 |
| Arthromyalgias | 95 |
| Low back pain | 10 |
| Morning stiffness | 8 |
| Asthenia/fatigue | 66 |
| Paraesthesia | 1 |
| Finger stings | 1 |
| Shortness of breath | 1 |
| Nausea | 1 |
| Burning mouth syndrome | 1 |
| Ocular pain | 1 |
| Dermatitis/urticaria | 1 |
| Multiple symptoms (arthromyalgias, asthenia, anxiety, panic attack, hallucinations, demoralisation, sleepiness, confusion, headache, memory deficit, dizziness, insomnia, vision loss, low-grade fever, chronic cough, paraesthesia, finger stings, chronic pharyngodynia, fast heartbeat, chronic itch, influenza syndrome, hand/foot ulcers, constipation, vaginosis and/or effluvium capillorum) | 25 |
| 2. Patients with objectifiable clinical manifestations likely due to SLE (condition 2) | 38/195 (19.5%) |
| Haematological involvement (i.e., lymphopenia, haemolytic anaemia)† | 10 |
| Monoarthritis | 10 |
| Proteinuria‡ | 6 |
| Recurrent infections leading to withdrawal/reduction of immunosuppressive therapy | 6 |
| Chilblain lupus erythematosus | 2 |
| Lower limbs sensory neuropathy | 1 |
| Lymphadenopathy | 1 |
| Hand pitting scars | 1 |
| Impaired diffusing capacity of the lung for carbon monoxide | 1 |
| Tachyarrhythmia | 1 |
| Venous thrombosis in secondary antiphospholipid syndrome | 1 |
| Hepatic-pancreatic enzyme increase | 1 |
| Depression | 1 |
*PGA was scored prior to reviewing complement and anti-DNA antibody test.
†not included in SLEDAI-2K.
‡Proteinuria ≤0.5 gr/day.
cSLEDAI-2K, clinical SLE disease activity index-2000; PGA, physician’s global assessment; SLE, systemic lupus erythematosus.